Dong-A ST concludes co-sale agreement of antihypertensive ‘Edarbi’ with Takeda

Published: 2017-09-01 15:01:40

Updated: 2017-09-01 15:01:40

Dong-A ST announced on the 30^th that conclusion of a joint sale and marketing agreement of ‘Edarbi,’ an ARB(angiotensin II receptor blocker) antihypertensive, with Takeda Pharmaceuticals Korea.

Under the agreement, Dong-A ST and Takeda Pharmaceuticals Korea will jointly carry out a business for general hospitals, and Dong-A ST will take charge in a business for regular hospitals and clinicals....

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.